CLBT

$14.69

Market ClosedAs of Mar 17, 8:00 PM UTC

Cellebrite DI Ltd.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

AAPLMSFTGOOGL

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$14.69
Potential Downside
54%
Whystock Fair Value$6.76
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorTechnology
IndustrySoftware - Infrastructure

Cellebrite DI Ltd. develops software and services for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company provides a platform of software solutions used to access, collect, review, ext...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.66B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
47.39
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.33
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
19.10%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.47

Recent News

Insider Monkey
Mar 17, 2026

Artisan Small Cap Fund Picked Cellebrite (CLBT) Following New Product Cycle Analysis

Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Small Cap Fund”. A copy of the letter can be downloaded here. The Fund seeks to invest in companies that possess franchise characteristics, with strong earnings trajectories, and are trading at a discount to the estimated private market value. Despite strong results […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Mar 9, 2026

What Gives Cellebrite DI Ltd. (CLBT) a Competitive Moat?

Voss Capital, LLC, an investment management company, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. Voss Capital’s funds, Voss Value Fund, LP, and the Voss Value Offshore Fund, Ltd returned -2.1% and -2.2%, respectively, to investors net of fees and expenses, in the fourth quarter compared to a […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 9, 2026

Cellebrite DI (CLBT) Valuation Check After Recent 7% Weekly Share Price Rebound

Cellebrite DI: recent performance snapshot Cellebrite DI (NasdaqGS:CLBT) has been on investors’ radar after a strong 7% move over the past week, contrasting with a negative past 3 months total return and weaker year to date and 1 year figures. At a last close of US$15.30, the digital forensics specialist carries a value score of 3, with reported annual revenue of US$475.675m and net income of US$77.813m from its legally sanctioned investigations software suite. See our latest analysis for...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Mar 8, 2026

Cellebrite DI Expands Case-to-Closure Platform With AI Tools, Corellium and Drone Forensics Update

Cellebrite DI (NASDAQ:CLBT) is expanding its “Case-to-Closure” platform with a growing set of digital forensics, evidence management, analytics, and AI-driven investigative tools, CFO Dave Barter said during a Morgan Stanley conference discussion. Barter described how the company’s products are used

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Feb 22, 2026

Does Cellebrite DI (CLBT) Offer Value After Recent Share Price Weakness?

If you are wondering whether Cellebrite DI's share price really lines up with its underlying worth, this article walks through the key valuation angles that matter for you. The stock last closed at US$13.16, with returns of 10.1% decline over 7 days, 17.1% decline over 30 days, 26.2% decline year to date, 31.2% decline over 1 year, 128.1% over 3 years and 26.3% over 5 years, pointing to shifting expectations over different time frames. Recent coverage has focused on Cellebrite DI's role in...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.